The fostamatinib was the spleen tyrosine kinase (SYK) inhibitor, and it was able to inhibit both parental and sorafenib-resistant (SR) HCC cell lines in vitro and xenograft models [88]. The gene discussed is SYK; the disease is hepatocellular carcinoma.